Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Initiates Coverage of Three Largest Healthcare Distributors

    William Blair initiated research coverage of McKesson Corporation (MCK $828.11), Cencora, Inc. (COR $308.19), and Cardinal Health, Inc. (CAH $199.85), the three largest healthcare distributors.

    Read more

  • Healthcare Reset

    After several years of headwinds—from post-COVID dynamics to policy pressures—greater visibility and durable demand drivers are revealing compelling entry points across high-quality healthcare names.

    Watch the video

  • Business Owners Forum – Rise of Private Capital

    Chris Brathwaite, partner, director of pre-liquidity planning, Kirsten Olsen, managing director and head of PWM Private Capital, and Anu Sharma, partner, managing director, and co-head of Venture Capital, host a conversation on how private markets are evolving and what that means for owners navigating today’s capital landscape.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures